As of 2025-07-05, the EV/EBITDA ratio of Foghorn Therapeutics Inc. (FHTX) is -2.58. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FHTX's latest enterprise value is 224.92 mil USD. FHTX's TTM EBITDA according to its financial statements is -87.08 mil USD. Dividing these 2 quantities gives us the above FHTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.0x - 13.1x | 12.8x |
| Forward P/E multiples | 17.1x - 32.0x | 20.6x |
| Fair Price | (25.65) - (19.40) | (25.00) |
| Upside | -600.0% - -478.2% | -587.2% |
| Date | EV/EBITDA |
| 2025-07-03 | -2.58 |
| 2025-07-02 | -2.47 |
| 2025-07-01 | -2.42 |
| 2025-06-30 | -2.31 |
| 2025-06-27 | -2.40 |
| 2025-06-26 | -2.41 |
| 2025-06-25 | -2.44 |
| 2025-06-24 | -2.42 |
| 2025-06-23 | -2.43 |
| 2025-06-20 | -2.32 |
| 2025-06-18 | -2.34 |
| 2025-06-17 | -2.37 |
| 2025-06-16 | -2.11 |
| 2025-06-13 | -2.06 |
| 2025-06-12 | -2.21 |
| 2025-06-11 | -2.23 |
| 2025-06-10 | -2.26 |
| 2025-06-09 | -2.24 |
| 2025-06-06 | -2.15 |
| 2025-06-05 | -1.94 |
| 2025-06-04 | -1.99 |
| 2025-06-03 | -2.09 |
| 2025-06-02 | -1.97 |
| 2025-05-30 | -1.91 |
| 2025-05-29 | -2.06 |
| 2025-05-28 | -2.05 |
| 2025-05-27 | -1.89 |
| 2025-05-23 | -1.95 |
| 2025-05-22 | -1.95 |
| 2025-05-21 | -1.90 |
| 2025-05-20 | -1.95 |
| 2025-05-19 | -1.99 |
| 2025-05-16 | -2.13 |
| 2025-05-15 | -2.06 |
| 2025-05-14 | -1.93 |
| 2025-05-13 | -2.07 |
| 2025-05-12 | -2.13 |
| 2025-05-09 | -1.99 |
| 2025-05-08 | -2.20 |
| 2025-05-07 | -1.85 |
| 2025-05-06 | -1.85 |
| 2025-05-05 | -1.78 |
| 2025-05-02 | -2.01 |
| 2025-05-01 | -1.96 |
| 2025-04-30 | -1.99 |
| 2025-04-29 | -2.02 |
| 2025-04-28 | -2.11 |
| 2025-04-25 | -2.09 |
| 2025-04-24 | -2.16 |
| 2025-04-23 | -2.29 |